Next Article in Journal
The Use of Orientation Templates and Free-Hand Implant Insertion in Artificial Mandibles—An Experimental Laboratory Examination in Fifth-Year Dental Students
Next Article in Special Issue
Animal Experiments in Periodontal and Peri-Implant Research: Are There Any Changes?
Previous Article in Journal
Wind Instrumentalists and Temporomandibular Disorder: From Diagnosis to Treatment
Previous Article in Special Issue
Meth Mouth—A Growing Epidemic in Dentistry?
Comment

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

1
Oncology Unit, Azienda Ospedaliera di Alessandria, 15121 Alessandria, Italy
2
Oral Medicine Unit, Università di Palermo, 90127 Palermo, Italy
3
Service D’épidémiologie et de Santé Publique, Hôpitaux Universitaires Paris-Sud, 94270 Paris, France
4
Haematology Unit, Azienda Ospedaliera di Alessandria, 15121 Alessandria, Italy
5
Regional Center for Prevention, Diagnosis and Treatment of Medication and Radiation-Related Bone Diseases of the Head and Neck, University of Padua, 35136 Padua, Italy
*
Author to whom correspondence should be addressed.
Received: 22 July 2018 / Revised: 22 August 2018 / Accepted: 27 August 2018 / Published: 1 September 2018
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. View Full-Text
Keywords: osteonecrosis of the jaw; ONJ; osteonecrosis; jaw; medication-related osteonecrosis of the jaw; MRONJ; multiple myeloma; denosumab; zoledronic acid osteonecrosis of the jaw; ONJ; osteonecrosis; jaw; medication-related osteonecrosis of the jaw; MRONJ; multiple myeloma; denosumab; zoledronic acid
MDPI and ACS Style

Fusco, V.; Campisi, G.; De Boissieu, P.; Monaco, F.; Baraldi, A.; Numico, G.; Bedogni, A. Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology. Dent. J. 2018, 6, 42. https://0-doi-org.brum.beds.ac.uk/10.3390/dj6030042

AMA Style

Fusco V, Campisi G, De Boissieu P, Monaco F, Baraldi A, Numico G, Bedogni A. Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology. Dentistry Journal. 2018; 6(3):42. https://0-doi-org.brum.beds.ac.uk/10.3390/dj6030042

Chicago/Turabian Style

Fusco, Vittorio, Giuseppina Campisi, Paul De Boissieu, Federico Monaco, Anna Baraldi, Gianmauro Numico, and Alberto Bedogni. 2018. "Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology" Dentistry Journal 6, no. 3: 42. https://0-doi-org.brum.beds.ac.uk/10.3390/dj6030042

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop